CN1333372A - 在体内容易吸收的蛋白化锌的制备方法 - Google Patents
在体内容易吸收的蛋白化锌的制备方法 Download PDFInfo
- Publication number
- CN1333372A CN1333372A CN01103060A CN01103060A CN1333372A CN 1333372 A CN1333372 A CN 1333372A CN 01103060 A CN01103060 A CN 01103060A CN 01103060 A CN01103060 A CN 01103060A CN 1333372 A CN1333372 A CN 1333372A
- Authority
- CN
- China
- Prior art keywords
- zinc
- oligopeptides
- potide
- preparation
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims description 72
- 239000011701 zinc Substances 0.000 title claims description 72
- 229910052725 zinc Inorganic materials 0.000 title claims description 72
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title description 2
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 45
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 108091005804 Peptidases Proteins 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims abstract description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims abstract 2
- 230000007935 neutral effect Effects 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 230000002797 proteolythic effect Effects 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 235000013361 beverage Nutrition 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000003531 protein hydrolysate Substances 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 229910001656 zinc mineral Inorganic materials 0.000 claims description 4
- 235000021120 animal protein Nutrition 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 230000017854 proteolysis Effects 0.000 abstract description 2
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000008367 deionised water Substances 0.000 abstract 1
- 229910021641 deionized water Inorganic materials 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 235000013305 food Nutrition 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 102000018146 globin Human genes 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000000290 insulinogenic effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N keto-D-fructose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Non-Alcoholic Beverages (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供蛋白化锌的制备方法,该蛋白化锌在体内容易吸收。将植物性或动物性蛋白质混悬于水中,添加蛋白水解酶、在pH3.5－6.0反应12小时,得到寡肽后,在蛋白水解物寡肽内添加锌无机离子,使发生螯合反应,得到锌寡肽。将该物浓缩至固体成份为35%左右后,干燥后粉碎,得到粉末状锌寡肽。
Description
本发明涉及在体内易于吸收的蛋白化锌的制造方法以及含有该成分的饮料或食品组合物，具体地说是将将动物性或植物性蛋白质混悬于水中，添加蛋白水解酶、在弱酸性条件下，使之长时间反应，得到寡肽(Oligopeptide)后，在蛋白分解物寡肽内添加锌无机离子，使之发生螯合(Chelation)反应，得到锌寡肽，将该物质浓缩后干燥、粉碎，得到粉末状锌寡肽。
以前使用的无机强化物质都是在体内不容易吸收的物质，而在消化道小肠内能够吸收的无机化合物是一种调钙蛋白(Calmodulin)样的东西，它是一种钙化合物，在人体内流通、被使用，对此已经得到证明。由发现调钙蛋白构造依存于螯合钙离子的寡肽，而引发锌无机物寡肽制备方法的发明。
锌不足是体内胰岛素活性降低的原因，并且发现体内锌不足这一现象的发生是由于吸收性锌的不足导致，于是决定发明锌寡肽。这是一种能够吸收的锌化合物。
由于现代人摄入过量的加工食品，引起抑制无机物吸收的物质含量增加以及由于人体老化而引起的吸收功能降低，致使在体液中应保有的无机物平衡出现失调，从而引起成年人疾病的增加，同时由于在体内的生理作用的改变，促进了癌这种异常变异物质的发生。其中，由于锌无机物不足引起的糖尿病不仅在成年人中发生、甚至扩展到在儿童，这是目前面临的现状。
根据汉方医学，锌的生理活性与调糖和精力有关。所谓调糖是指糖的调节，相当于糖尿疾病，也与维持机体的能量的产生有关。体内糖的调节不正常时，由于能量的作用，所有生理活动处于活跃状态，与此相反，因为将糖转化为能量的代谢功能不能维持正常状态，不仅对于外部入侵的病原菌无法抵御，对于体内发生的病毒，抵抗力也会下降，从而诱发疾病。锌作为必须无机物在胰岛素活化中发挥作用。其中胰岛素能再生肌肉组织和神经组织、将糖转化为能量。即便在血流中有足够的胰岛素，如果没有锌无机物的话，也不能够发挥胰岛素的作用(Beneficial in diabetics)。这与使淀粉转化为糖(saccharification)的淀粉酶(Amylase)一样，该酶如果没有钙无机物协同作用，就不具有作为糖化酶的功能。
锌无机物的重要生理作用在于①活化胰岛素(Diabetestreatment)；②通过胰岛素的活化生产充足的能量、诱导发挥最大的精力(increase male potency and sex drive)；③抑制变异物质的发生和增强抗癌(prevent cancer)作用，在DNA重合中必须的催化作用与迅速的组织再生有关、对于活跃的伤治愈(Accelerates woundhealing)及前列腺相关疾病(Prevents prostate problems)、预防粉刺的生成(Treatment of Rheumatoid)、预防脱发(Prevents hairloss)、类风湿性关节炎治疗(Treatment of Rheumatoid arthritis)等均给予影响。
根据最近的研究结果，由于摄取了足够的锌，儿童疾病得到了显著的降低。也有报道称在给儿童补充了锌的情况下，肺炎的发生率降低40％、腹泻的发生率降低25％。另外，认为糖尿病是由于锌无机物的不足而引起的疾病。糖消耗减少现象的发生是由于胰岛素活性降低所致。因为胰岛素活性降低时糖的消耗减少、能量生成不足，由于体力降低，连活动也无法自由进行。胰岛素必须是非胰岛素原的功能性胰岛素，只有在1分子(分子量：6,615)功能性胰岛素中结合1个原子锌(原子量：65)的情况下，胰岛素才具有活性。在比例上，分子量1,000的胰岛素必须有一个锌相伴随。作为医学界使用的胰岛素制剂皮下注射锌珠蛋白胰岛素(Globin zinc I)，也是在胰岛素伴有锌无机物时才有效。
一般认为，过去只发生于老年人的糖尿病，现在之所以在儿童也会发生这与遗传无关，原因在于饮食类型。儿童喜爱的油炸食品诱发脂肪(fat)的过量摄取，而脂肪可抑制锌无机物的活动，过多摄取简易的方便食品时，造成磷酸过量，不仅仅是锌、对钙的活动也会带来障碍。无论对何种形式的无机物，脂肪质和磷酸盐都会积极地防碍其吸收。物质在体内被消耗或者自身补充不足的成分这是机体与生具有的机能，对于使该机能降低的物质，在摄取时应该有所节制。由影响物质引起的补充机能的丧失，会出现不足产生不足的现象。锌的不足致使胰岛素活性降低，因为未被消耗的残留胰岛素多余，致使胰脏产生的胰岛素减少或停止。该现象可从运动员与普通人的比较得到证实，即消耗大量能量的运动员比普通人的锌含量高20倍。这是因为锌促使胰岛素的生成，从而使糖代谢进行活泼的缘故。因此，能解决无机物不足的物质必须是可吸收态的化合物，易于吸收的无机化合物都是无机物寡肽(Mineral-Oligopeptide)、这是在机体内活动的无机结构物。锌无机物是图1所示的吸收性锌(Absorptive Zinc-Oligopeptide)结构物。
本发明的目的在于制造在体内容易吸收的蛋白化锌，其形态为水溶性蛋白质的寡肽螯合锌无机物而成的形态。
为达成上述目的，本发明由以下步骤构成：将蛋白质混悬于纯水中，添加蛋白水解酶，在中性条件下，使其长时间反应，得到寡肽；在蛋白水解物的寡肽内添加锌无机离子，使之发生螯合反应，得到锌寡肽；浓缩上述锌寡肽后，干燥、制成粉末状锌寡肽。
上述蛋白质是植物性或动物性蛋白的任意一种，蛋白水解酶使用蛋白酶。
一方面，在本发明的粉末或液体状锌寡肽内，从下列物质中选择一种以上成分混合，能够制成在体内易于吸收的蛋白化锌饮料。这些供选择的物质是维生素C、维生素B1、维生素B2、果糖，纯水、α-水解加工淀粉以及硬脂酸镁。
进一步说明为：使用所选择的一种以上成分，它们是：锌寡肽99.5％、维生素C 0.01-0.05％、维生素B1 0.01-0.05％、维生素B20.01-0.05％、或α-水解加工淀粉4.0-5.0％及硬脂酸镁0.01-0.05％。
以下，通过实施例说明本发明。但这些实施例并不限定本发明的技术范围。
<实施例1>
植物性豆蛋白质和谷蛋白，动物性蛋白质酪蛋白和明胶全都可以作为蛋白质使用。其中，将纯度为95％以上的蛋白质100％混悬于800％的水中，添加3％蛋白水解酶的蛋白酶，在pH3.5-6.0使其反应12小时，得到寡肽。此时，蛋白水解物中，非水溶性氨基酸能够分离，过滤除去。其次，在蛋白水解物寡肽1,000％中，经计算加入1原子量锌无机离子，使之反应后，得到锌寡肽。将该物浓缩至固型成分为35％左右后，用喷雾干燥机干燥，收取粉末状锌寡肽。
<实施例2>
在实施例1，将锌寡肽溶液调整至28％的溶液，如下表1进行配伍，锌的推荐量(RDA：Recommended Dietary Allowance)设定为12-15mg/l日的基准，制造锌寡肽。
表1：饮料水的组合物
| 成分 | 添加量 |
| 28％锌寡肽溶液 | 1.0％ |
| 维生素B1 | 0.01％ |
| 果糖 | 12％ |
| 维生素C | 0.03％ |
| 维生素B2 | 0.01％ |
| 纯水 | 86.95％ |
| 合计 | 100％ |
<实施例3>
将实施例1得到的粉末状锌寡肽按表2进行配伍，填充0.5g于胶囊内，制备锌强化健康食品。
表2：锌强化健康食品胶囊的组成成分
| 成分 | 添加量 |
| 粉末状锌寡肽 | 99.95％ |
| 维生素B1 | 0.01％ |
| 维生素C | 0.03％ |
| 维生素B2 | 0.01％ |
| 合计 | 100％ |
<实施例4>
将实施例1得到的粉末状锌寡肽按表2进行配伍，压片，每片0.5g，制备锌强化健康食品。
表3：锌强化健康食品压片的组成成分
| 成分 | 添加量 |
| 粉末状锌寡肽 | 94.95％ |
| 维生素B1 | 0.01％ |
| α-水解加工淀粉 | 4.7％ |
| 维生素C | 0.03％ |
| 维生素B2 | 0.01％ |
| 硬脂酸镁 | 0.3％ |
| 合计 | 100％ |
如上所述，本发明的吸收性锌寡肽分子量是800-1,000，它比分子量24,000-28,000的整合蛋白质小，该整合蛋白质能在小肠粘膜吸收，因此锌寡肽容易吸收，因为是将水溶性蛋白质的寡肽螯合了锌无机物，所以也不受消化道内食品成分的干扰，在体内锌容易吸收。
图1显示的是本发明的吸收性锌寡肽结构物。
图2显示的是寡肽。
Claims (6)
1.在体内容易吸收的蛋白化锌的制备方法，其特征在于含有以下步骤：将蛋白质混悬于纯水中，添加蛋白水解酶、在中性范围，使之长时间反应，得到寡肽；在蛋白水解物多肽内添加锌无机离子，使之发生螯合反应，得到锌寡肽；浓缩上述锌寡肽后，干燥，制备粉末状锌寡肽。
2.权利要求1记载的在体内容易吸收的蛋白化锌的制备方法，其特征在于含有以下步骤：将100％蛋白质混悬于纯水800％中，添加2％-4％蛋白酶这种蛋白水解酶，在pH3.5-6.0，反应10-12小时，得到寡肽；在1,000份蛋白水解物多肽内加入1原子量的无机锌离子，使之发生螯合反应，得到锌寡肽；将上述锌寡肽浓缩至固型成分为32％-36％后，进行干燥，制备成粉末状锌寡肽。
3.权利要求1记载的在体内易于吸收的蛋白化锌的制备方法，其特征在于蛋白质是植物性或动物性蛋白质的任意一种，蛋白水解酶是蛋白酶。
4.蛋白化锌饮料，其中该饮料的蛋白化锌在体内容易吸收，制备方法为：在权利要求1中得到的粉末状或液体状锌寡肽中，加入选自维生素C、维生素B1、维生素B2、果糖，纯水、α-水解加工淀粉以及硬脂酸镁中一种以上成分，混合，制备而成。
5.权利要求4的蛋白化锌饮料，其特征在于上述成分是从锌寡肽99.5％、维生素C0.01-0.05％、维生素B10.01-0.05％、维生素B20.01-0.05％、或α-水解加工淀粉4.0-5.0％及硬脂酸镁0.01-0.05％中选择一种以上的成分。
6.蛋白化锌胶囊或片剂，其特征在于通过除去权利要求4的蛋白化锌饮料的水分，制备而成。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR39595/2000 | 2000-07-11 | ||
| KR10-2000-0039595A KR100421466B1 (ko) | 2000-07-11 | 2000-07-11 | 체내에 흡수되기 용이한 아연-올리고펩티드의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1333372A true CN1333372A (zh) | 2002-01-30 |
Family
ID=19677374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01103060A Pending CN1333372A (zh) | 2000-07-11 | 2001-01-22 | 在体内容易吸收的蛋白化锌的制备方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6740502B2 (zh) |
| EP (1) | EP1172373B1 (zh) |
| JP (1) | JP2002034592A (zh) |
| KR (1) | KR100421466B1 (zh) |
| CN (1) | CN1333372A (zh) |
| DE (1) | DE60138855D1 (zh) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102174073A (zh) * | 2010-12-17 | 2011-09-07 | 中国海洋大学 | 一种牡蛎蛋白肽-锌螯合物及其制备方法 |
| CN101283805B (zh) * | 2008-05-22 | 2011-11-30 | 广州大学 | 一种锌-多肽配合物及其制备方法和应用 |
| CN105695547A (zh) * | 2016-03-30 | 2016-06-22 | 福建农林大学 | 一种灰树花蛋白肽-硒螯合物的制备方法 |
| CN105768112A (zh) * | 2016-03-30 | 2016-07-20 | 福建农林大学 | 一种食药用菌蛋白肽-锌螯合物的制备方法 |
| CN105768086A (zh) * | 2016-03-30 | 2016-07-20 | 福建农林大学 | 一种食用菌蛋白肽-硒螯合物的制备方法 |
| CN105821104A (zh) * | 2016-03-30 | 2016-08-03 | 福建农林大学 | 一种食用菌蛋白肽-钙螯合物的制备方法 |
| CN106309375A (zh) * | 2016-10-11 | 2017-01-11 | 中国科学院过程工程研究所 | 一种纳米粒制剂、其制备方法及应用 |
| CN107411100A (zh) * | 2017-05-04 | 2017-12-01 | 济南大学 | 一种制备高f值玉米寡肽‑锌螯合物的方法 |
| CN111329070A (zh) * | 2020-03-06 | 2020-06-26 | 常熟理工学院 | 河蚬抗氧化肽锌制剂口服液 |
| CN111387508A (zh) * | 2020-03-12 | 2020-07-10 | 大连工业大学 | 一种锌螯合肽凝胶及其制备方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040013549A (ko) * | 2002-08-07 | 2004-02-14 | 정홍섭 | 인삼가공물 및 그 가공방법 |
| JP4719465B2 (ja) * | 2002-09-04 | 2011-07-06 | ディーエスエム アイピー アセッツ ビー．ブイ． | インスリン感受性増強剤およびペプチド画分を含む栄養補給用および治療用組成物 |
| EP1540815B1 (en) | 2002-09-06 | 2006-12-27 | Telefonaktiebolaget LM Ericsson (publ) | Composite power amplifier |
| JP3769267B2 (ja) * | 2002-12-05 | 2006-04-19 | 順一 有田 | 亜鉛増強食品及びその製造方法 |
| US20090271021A1 (en) * | 2008-04-28 | 2009-10-29 | Popp Shane M | Execution system for the monitoring and execution of insulin manufacture |
| JP2010132524A (ja) * | 2008-11-06 | 2010-06-17 | Nokodai Tlo Kk | ペプチドキレート含有肥料 |
| WO2014186587A1 (en) * | 2013-05-15 | 2014-11-20 | Syracuse University | Methods and systems for zinc delivery using intrinsic factor or haptocorrin |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4020158A (en) * | 1975-08-08 | 1977-04-26 | Ashmead H H | Increasing metals in biological tissue |
| US3969540A (en) * | 1975-09-11 | 1976-07-13 | Albion Laboratories, Inc. | Enzymatically prepared metal proteinates |
| US4076803A (en) * | 1976-03-15 | 1978-02-28 | Ashmead H H | Synergistic combination of metal proteinates with beta-chlorovinyl dialkyl phosphates |
| US4201793A (en) * | 1976-11-19 | 1980-05-06 | Ashmead H H | Oil cooked foods containing metal proteinates |
| NZ183858A (en) * | 1976-12-17 | 1979-10-25 | Ashmead Hh | Polyvalent metal proteinates as food additives |
| US4680276A (en) * | 1977-05-25 | 1987-07-14 | Institut National De La Sante Et De La Recherche Medicale | Metal polypeptides |
| US4172072A (en) * | 1977-10-20 | 1979-10-23 | Ashmead H H | Buffered enzymatically produced metal proteinates |
| US4216143A (en) * | 1977-10-20 | 1980-08-05 | Ashmead H H | Soluble non-ferrous metal proteinates |
| US4390450A (en) * | 1980-07-30 | 1983-06-28 | A. E. Staley Manufacturing Company | Proteinaceous foaming compositions and method for preparing foamed proteinaceous products |
| FR2491922A1 (fr) * | 1980-10-14 | 1982-04-16 | Roussel Uclaf | Nouveaux hexapeptides, procede pour leur preparation et application comme medicaments |
| US4599152A (en) * | 1985-05-24 | 1986-07-08 | Albion Laboratories | Pure amino acid chelates |
| US4774089A (en) * | 1985-06-14 | 1988-09-27 | Albion International, Inc. | Stimulation of gonadotropic hormones with mineral mixtures containing amino acid chelates |
| US4863898A (en) * | 1986-02-06 | 1989-09-05 | Albion International, Inc. | Amino acid chelated compositions for delivery to specific biological tissue sites |
| US4830716B1 (en) * | 1986-07-03 | 1999-12-07 | Albion Int | Preparation of pharmaceutical grade amino acid chelates |
| US5292538A (en) * | 1992-07-22 | 1994-03-08 | Metagenics, Inc. | Improved sustained energy and anabolic composition and method of making |
| US5997908A (en) * | 1992-10-22 | 1999-12-07 | Song; Moon K. | Prostate extract supplemented with zinc |
| US5516925A (en) * | 1994-08-23 | 1996-05-14 | Albion International, Inc. | Amino acid chelates having improved palatability |
| BR9611253A (pt) * | 1995-10-27 | 1999-03-30 | Procter & Gamble | Misturas bebíveis secas fortificadas por ferro zinco e vitaminas de cor estável |
| US6071545A (en) * | 1999-02-03 | 2000-06-06 | Vyrex Corporation | Metallic oligopeptide complexes |
| US6166071A (en) * | 2000-03-13 | 2000-12-26 | Albion International, Inc. | Zinc amino acid chelates having ligands comprised of glycine and a sulfur-containing amino acids |
-
2000
- 2000-07-11 KR KR10-2000-0039595A patent/KR100421466B1/ko not_active IP Right Cessation
- 2000-12-07 US US09/730,542 patent/US6740502B2/en not_active Expired - Fee Related
- 2000-12-13 JP JP2000379180A patent/JP2002034592A/ja active Pending
-
2001
- 2001-01-22 CN CN01103060A patent/CN1333372A/zh active Pending
- 2001-03-06 EP EP01710010A patent/EP1172373B1/en not_active Expired - Lifetime
- 2001-03-06 DE DE60138855T patent/DE60138855D1/de not_active Expired - Lifetime
-
2003
- 2003-12-15 US US10/734,172 patent/US6867176B2/en not_active Expired - Fee Related
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101283805B (zh) * | 2008-05-22 | 2011-11-30 | 广州大学 | 一种锌-多肽配合物及其制备方法和应用 |
| CN102174073A (zh) * | 2010-12-17 | 2011-09-07 | 中国海洋大学 | 一种牡蛎蛋白肽-锌螯合物及其制备方法 |
| CN105695547A (zh) * | 2016-03-30 | 2016-06-22 | 福建农林大学 | 一种灰树花蛋白肽-硒螯合物的制备方法 |
| CN105768112A (zh) * | 2016-03-30 | 2016-07-20 | 福建农林大学 | 一种食药用菌蛋白肽-锌螯合物的制备方法 |
| CN105768086A (zh) * | 2016-03-30 | 2016-07-20 | 福建农林大学 | 一种食用菌蛋白肽-硒螯合物的制备方法 |
| CN105821104A (zh) * | 2016-03-30 | 2016-08-03 | 福建农林大学 | 一种食用菌蛋白肽-钙螯合物的制备方法 |
| CN106309375A (zh) * | 2016-10-11 | 2017-01-11 | 中国科学院过程工程研究所 | 一种纳米粒制剂、其制备方法及应用 |
| CN107411100A (zh) * | 2017-05-04 | 2017-12-01 | 济南大学 | 一种制备高f值玉米寡肽‑锌螯合物的方法 |
| CN111329070A (zh) * | 2020-03-06 | 2020-06-26 | 常熟理工学院 | 河蚬抗氧化肽锌制剂口服液 |
| CN111387508A (zh) * | 2020-03-12 | 2020-07-10 | 大连工业大学 | 一种锌螯合肽凝胶及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100421466B1 (ko) | 2004-03-10 |
| EP1172373A2 (en) | 2002-01-16 |
| US20040126410A1 (en) | 2004-07-01 |
| EP1172373B1 (en) | 2009-06-03 |
| JP2002034592A (ja) | 2002-02-05 |
| DE60138855D1 (de) | 2009-07-16 |
| KR20020006114A (ko) | 2002-01-19 |
| US6867176B2 (en) | 2005-03-15 |
| US6740502B2 (en) | 2004-05-25 |
| EP1172373A3 (en) | 2002-04-10 |
| US20020028769A1 (en) | 2002-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1333372A (zh) | 在体内容易吸收的蛋白化锌的制备方法 | |
| CN101953442A (zh) | 一种具有降血糖功能的保健品 | |
| CN109363006A (zh) | 一种胶原蛋白肽饮品 | |
| CN101537174A (zh) | 养生钙 | |
| CN1961957A (zh) | 一种抗衰老结肠吸收制剂 | |
| KR20170104575A (ko) | 신부전 환자를 치료하기 위한 카복실산 혼합물 | |
| CN104546955A (zh) | 一种原猕猴桃味维生素c钠口含片及其制备工艺 | |
| CN104757560A (zh) | 一种谷胱甘肽酵母酶解组合物及其制备方法 | |
| CN105661547A (zh) | 一种益生菌复配蚕桑的糖尿病人营养补充剂 | |
| CN100490896C (zh) | 排铅口嚼片及其制备方法 | |
| CN101642468A (zh) | 用于降低血糖和血脂的药物组合物 | |
| CN101032523B (zh) | 一种蜂王浆酸钙及其制备方法 | |
| JP2008237058A (ja) | 栄養補助食品 | |
| EP0791357A2 (en) | Use of gluten peptides as stimulator of mineral absorption and preventive agent of hyperlipidermia and hypercholesterolemia | |
| CN101129406A (zh) | 复方阿胶系列产品的配方和制造方法 | |
| KR20170069462A (ko) | 은행잎 추출물 및 차전자피 분말을 함유한 혈액개선용 건강보조식품 | |
| KR100734944B1 (ko) | 젖산칼슘 및 미강을 주재로 한 기능성 건강식품 조성물 | |
| KR20200107809A (ko) | 자일리톨 및/또는 효소처리 스테비아로 피복된 복합비타민 과립제 | |
| CN1211492C (zh) | 用酶制备易于体内吸收的蛋白化－钙的方法及利用该种蛋白化－钙生产的保健食品 | |
| CN100551357C (zh) | 云芝菌丝体在制备抗疲劳药剂中的应用 | |
| JP2005213234A (ja) | 抗酸化栄養組成物 | |
| CN1185316A (zh) | 含有糖精锌的药物制剂 | |
| KR20050092974A (ko) | 당뇨병 예방 및 치료 보조용 건강식품 | |
| CN1279949A (zh) | 一种复合降糖营养素 | |
| CN104544114A (zh) | 一种复合维生素含片 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |